Group 1: Market Overview - The stock market has shown impressive performance in 2024, with the SPDR S&P 500 ETF (NYSE: SPY) up over 21% year-to-date and trading at all-time highs [1] - Investors are chasing high-flying stocks, but this approach carries risks as stocks at all-time highs may face corrections [1] - Focusing on oversold stocks with solid risk-to-reward ratios may be a more rewarding strategy [1] Group 2: Micron Technology - Micron Technology, Inc. (NASDAQ: MU) reported strong earnings on September 25th, with an EPS of $1.18, beating estimates by $0.21, and revenue of $7.75 billion, up 93.3% year-over-year [2][4] - Despite a pullback from a high of $114.8 to $101.7, the stock has found support and is poised for an upward trend, presenting an attractive risk-reward opportunity [2][4] - Analysts have a Moderate Buy consensus on Micron, with a price target of $142.85 indicating a potential upside of 40.5% [3][4] Group 3: Biogen Inc. - Biogen Inc. (NASDAQ: BIIB) has seen its stock decline nearly 30% year-to-date, placing it in oversold and undervalued territory, with an RSI of 36 [5][6] - The stock's P/E ratio of 23.4 and forward P/E of 10.82 suggest a valuation that could attract long-term investors [5] - Biogen reported Q2 results with an EPS of $5.28, beating expectations by $1.28, on revenue of $2.47 billion, with a modest year-over-year growth of 0.4% [5][6] Group 4: Regeneron Pharmaceuticals - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has pulled back to a critical support level at its 200-day simple moving average (SMA) near $1,000 [7] - The stock's last encounter with this moving average saw it surge from $900 to nearly $1,200 within four months [7] - Regeneron reported Q2 earnings with an EPS of $11.56, surpassing estimates by $2.63, and revenue of $3.55 billion, a 12.3% year-over-year increase [8][9]

Designation is based on data from the clinical development program which demonstrated clinical proof of conceptFelzartamab, an investigational anti-CD38 monoclonal antibody, is a potential first-in-class therapeutic candidate for a range of rare immune-mediated indications with planning underway for Phase 3 developmentFDA Breakthrough Therapy Designation is intended to expedite the development and review of drugs for serious or life-threatening conditions and which have potential to show substantial improve ...

Findings from Part B and Part C of the DEVOTE study support the clinical benefits of a higher dose regimen of nusinersen (50/28 mg) in both individuals previously treated and treatment-naïve to nusinersen Investigational regimen also shows more rapid slowing of neurodegeneration, as measured by neurofilamentBiogen plans to submit regulatory applications around the world for approval of the nusinersen higher dose regimen CAMBRIDGE, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today ann ...

Biogen Inc. (BIIB) , along with its Belgian partner UCB, announced positive topline data from the phase III PHOENYCS GO study, which evaluated the investigational drug candidate, dapirolizumab pegol, for the treatment of moderate-to-severe systemic lupus erythematosus (SLE).SLE is a chronic and debilitating autoimmune disease that can affect multiple organ systems.The study met the primary endpoint by demonstrating clinical improvement in moderate-to-severe SLE.Year to date, shares of Biogen have plunged 25 ...

Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in moderate-to-severe systemic lupus erythematosus; Clinical improvements were observed among key secondary endpoints measuring disease activity and flares.UCB and Biogen are advancing dapirolizumab pegol with the objective to address the substantial unmet medical need for people living with SLE, where there are limited treatment options.SLE is a chronic, debilitating autoimmune disease that affects multiple organ systems ...

OPUVIZ™, a biosimilar referencing Eylea1 (aflibercept), is Samsung Bioepis and Biogen’s second ophthalmology biosimilar to be recommended for marketing authorization by the European Medicines Agency INCHEON, South Korea and CAMBRIDGE, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for OPUVIZ™ 40 mg/mL solution for ...

Biogen Inc. (NASDAQ:BIIB) Cantor Fitzgerald Global Healthcare Conference Call September 18, 2024 1:20 PM ET Company Participants Chuck Triano - Head, Investor Relations Conference Call Participants Eric Schmidt - Cantor Fitzgerald Eric Schmidt Good afternoon, everyone. If you could take a seat? My name is Eric Schmidt, and my pleasure to host this next fireside chat with Biogen. We're delighted to have with us today Chuck Triano, who heads the IR group there at Biogen. Chuck, thank you very much for joining ...

Core Insights - The systemic lupus erythematosus (SLE) treatment landscape is evolving with multiple new therapies in development, including Biogen's litifilimab, AbbVie's Rinvoq, and Bristol Myers Squibb's Sotyktu [1][6] - Rheumatologists view litifilimab as a strong competitor to established biologics, showing a 26% improvement in SRI-4 response over placebo in Phase II trials [2][3] - Rinvoq and Sotyktu have also shown positive Phase II efficacy data, appealing to rheumatologists and patients due to their oral administration [3][4] Emerging Therapies - Rheumatologists are particularly interested in the approval of Rinvoq, Sotyktu, and litifilimab for SLE, especially for skin manifestations [4] - New therapies will need to compete with Benlysta, which remains a preferred choice due to its established safety record and familiarity among rheumatologists [4][5] - AstraZeneca's Saphnelo and Aurinia's Lupkynis have successfully targeted specific patient populations, indicating the importance of niche marketing for new entrants [5] Market Dynamics - As new therapies approach regulatory approval, they are expected to diversify treatment options for SLE patients, but must demonstrate strong efficacy, safety, and ease of administration [6] - The competitive landscape is influenced by the established dominance of Benlysta, which has a strong market presence in both SLE and lupus nephritis [4][6] - Spherix Global Insights provides strategic guidance and market analysis, helping stakeholders navigate the evolving specialty markets [6][7]

Core Insights - Biogen Inc. has appointed two new independent directors, Lloyd B. Minor, M.D., and Sir Menelas Pangalos, Ph.D., to enhance its Board of Directors, effective October 1, 2024, and January 1, 2025, respectively [1][2] Group 1: New Appointments - Dr. Lloyd B. Minor is the Dean of the Stanford University School of Medicine and has extensive experience in leading health and medicine strategy, previously serving as Provost at Johns Hopkins University [2][3] - Sir Menelas Pangalos was the Executive Vice President of Biopharmaceuticals R&D at AstraZeneca, where he oversaw R&D from discovery to late-stage development, and has held senior roles at Pfizer, Wyeth, and GSK [4][5] Group 2: Contributions to Biogen - The new directors are expected to bring significant experience in R&D within the life sciences and biopharmaceutical industries, contributing to Biogen's portfolio and long-term growth [2][6] - Biogen's President and CEO, Christopher A. Viehbacher, emphasized that their collective expertise will be instrumental in advancing the company into its next chapter of sustainable growth [6] Group 3: Company Background - Biogen, founded in 1978, is a leading biotechnology company focused on innovative science to deliver new medicines and create value for shareholders and communities [7]

Comparable clinical efficacy and safety in Treatment Period 2 (TP2, Week 24-48) is maintained after switch from reference tocilizumab to TOFIDENCE (BAT1806/BIIB800)Phase 3 clinical data in totality demonstrates biosimilarity between TOFIDENCE (BAT1806/BIIB800) and reference tocilizumab before and after switching.1,2GUANGZHOU, China, Sept. 11, 2024 /PRNewswire/ -- Bio-Thera Solutions, Ltd. today announced, in collaboration with Biogen, the publication in the journal Arthritis Research & Therapy of results fr ...